Teva Pharmaceutical Industries (TEVA) Gross Profit (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Gross Profit came in at $2.2 billion in Q2 2026, up 2.43% YoY from $2.1 billion in Q2 2025, and up 9.18% on a QoQ basis from $2.0 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Gross Profit (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Gross Profit data on file, last reported at $2.2 billion in Q2 2026.
- Quarterly Gross Profit rose 2.43% year-over-year to $2.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.1 billion (up 10.15% YoY) and the FY2025 annual result came in at $8.9 billion, up 10.84% from the prior year.
- Gross Profit rose to $2.2 billion in Q2 2026, from $2.0 billion in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $2.7 billion in Q4 2025 to a low of $1.6 billion in Q1 2023.
- A 5-year average of $2.0 billion and a median of $1.9 billion in 2025 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2022 — Gross Profit decreased 13.66% — and 2023, when it jumped 36.5%.
- Tracing TEVA's Gross Profit over 5 years: stood at $1.8 billion in 2022, then soared by 36.5% to $2.4 billion in 2023, then slipped by 12.21% to $2.1 billion in 2024, then grew by 25.22% to $2.7 billion in 2025, then slipped by 18.94% to $2.2 billion in 2026.
- The last three Gross Profit figures came in at $2.2 billion (Q2 2026), $2.0 billion (Q1 2026), and $2.7 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|